{"id":27612,"date":"2025-02-22T00:01:46","date_gmt":"2025-02-21T16:01:46","guid":{"rendered":"https:\/\/flcube.com\/?p=27612"},"modified":"2025-02-22T00:01:48","modified_gmt":"2025-02-21T16:01:48","slug":"china-outlines-drug-pricing-reforms-encourages-insurance-funds-for-innovation","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=27612","title":{"rendered":"China Outlines Drug Pricing Reforms, Encourages Insurance Funds for Innovation"},"content":{"rendered":"\n
The Chinese government has released a set of opinions detailing the establishment of a new drug price formation mechanism by 2027, aiming to reduce financing costs for the innovative drug industry and support pharmaceutical innovation.<\/p>\n\n\n\n
Insurance Fund Role<\/strong> The document encourages commercial insurance companies to establish or clarify existing investment funds focused on the innovative drug industry. This leverages the long-term stability of insurance funds to support drug development and reduce financing costs.<\/p>\n\n\n\n
Self-Evaluation System<\/strong> A self-evaluation system for newly listed drugs will be implemented, requiring pharmaceutical companies to conduct truthful self-assessments and independent pricing. This system aims to enhance transparency and ensure fair market competition.<\/p>\n\n\n\n
National Reimbursement Drug List (NRDL)<\/strong> Pharmaceutical companies must supply NRDL negotiation drugs to designated medical institutions at agreed prices not exceeding payment standards. For non-designated institutions, market prices are not subject to these standards. Real-world analysis on Class C and NRDL-listed drugs will be conducted to evaluate clinical efficacy and economics, informing dynamic adjustments to the lists.<\/p>\n\n\n\n
Multi-Level Medical Security<\/strong> A comprehensive medical security system will be established, incorporating commercial health insurance, public welfare, and charity to broaden payment channels for innovative drugs. A commercial health insurance drug list (Class C) will be developed to expand drug coverage.<\/p>\n\n\n\n
Retail Pharmacy Pricing<\/strong> Drug prices in retail pharmacies will be independently set by operators and formed through market competition. Open price comparisons in designated pharmacies will promote fair competition, leveraging online transparency to guide reasonable pricing both online and offline.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"